68Ga-FAPI-LM3

N/A

Report date: 2025/11/20 16:00:32
NME

Base Information

Drug Name68Ga-FAPI-LM3
Drug Alias Name68Ga-FAPI-LM3
ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSomatostatin receptor 2 modulatorsFibroblast activation protein alpha modulators
TargetsSomatostatin receptor 2Prolyl endopeptidase FAP
Therapy Area/IndicationsAdenomatous Polyposis Coli
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesThe First Affiliated Hospital Of Xiamen University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen University
Inactive CompaniesN/A
Active IndicationsAdenomatous Polyposis Coli
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A